ERAs have been used to treat PAH, and more recently, aprocitentan has been approved for managing resistant hypertension.5 Angiotensinogen inhibitors (AGTis) inhibit the renin-angiotensinogen-aldosterone system (RAAS) at its origin. The gene discussed is AGT; the disease is Hypertension.